Company Technologies Markets Collaborations Investors Careers Contact Search IN THE NEWS 9/26/2017 Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 9/19/2017 Oxitec to Build State-of-the-Art Mosquito Egg Production Unit 9/18/2017 ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting 9/05/2017 Oxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials 9/01/2017 ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit 8/31/2017 Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis 8/31/2017 Intrexon to Participate in Upcoming Investor Conferences ENGINEERING SOLUTIONS Oxitec's Vector Control Solution: A Paradigm Shift in Mosquito Control Forging a New Frontier in Cellular Therapeutics: Oral ActoBiotics® Biopharmaceuticals Precise Gene Expression: Proprietary RheoSwitch® Technology Platform Company Synthetic Biology Our Platform Operating Units & Divisions Subsidiaries Management Board of Directors Our Commitment Technologies UltraVector® RheoSwitch® Cell Systems Informatics Protein Engineering AttSite™ Recombinases LEAP® Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics® Porcine Research Models BeyondBio™ Scientific Literature Markets Health Food Energy Environment Consumer Collaborations Exclusive Channel Collaborations Joint Ventures Private Companies Intrexon Institute for Biomolecular Research Partnering Opportunities Investors Overview Press Releases Collaborator News Stock Information Corporate Governance SEC Filings Events/Conferences Investors Packet FAQ Information Request IRS Form 8937 Careers Contact Legal Notices © 2017 Intrexon